https://biotechmorning.com/news/lilly-zepbound-vial-pricing-trick Biotech Morning en 2026-07-31T14:28:19.367Z Eli Lilly's Sneaky Pricing Trick That Could Change Who Gets Zepbound https://biotechmorning.com/news/ipsen-kartos-navtemadlin-myelofibrosis-deal Biotech Morning en 2026-07-31T14:27:26.719Z Ipsen's $1.75 Billion Bet on a Protein That Guards Cancer Cells https://biotechmorning.com/news/fda-real-time-clinical-trials-operation-trailblazer Biotech Morning en 2026-07-31T14:26:38.435Z The FDA Wants to Watch Your Clinical Trial Live https://biotechmorning.com/news/first-base-edited-human-embryo Biotech Morning en 2026-07-31T14:25:47.026Z Scientists Just Edited a Human Embryo Without Cutting Its DNA https://biotechmorning.com/news/biomarin-inozyme-phase-3-failure Biotech Morning en 2026-07-31T14:24:54.411Z BioMarin Paid $270M for a Drug That Can't Fix Bones https://biotechmorning.com/news/pharma-2-trillion-forecast-asterisk Biotech Morning en 2026-07-31T14:24:00.677Z Pharma's $2 Trillion Moonshot Has One Giant Asterisk https://biotechmorning.com/news/vera-therapeutics-trutakna-fda-approval-igan Biotech Morning en 2026-07-31T14:23:05.473Z The $425K-a-Year Kidney Drug That Just Got the Green Light https://biotechmorning.com/news/astrazeneca-2-billion-copd-merck-ohtuvayre-challenger Biotech Morning en 2026-07-31T14:22:13.040Z AstraZeneca Just Spent $2.1 Billion to Pick a Fight With Merck https://biotechmorning.com/news/bms-printing-money-clock-ticking Biotech Morning en 2026-07-31T14:21:26.425Z BMS Is Printing Money Right Now. The Clock Is Ticking. https://biotechmorning.com/news/non-viral-car-t-tcx-001-first-in-human-trial Biotech Morning en 2026-07-31T14:20:30.483Z The CAR-T That Ditched Viruses Entirely https://biotechmorning.com/news/spudcell-synthetic-cell-built-from-scratch Biotech Morning en 2026-07-31T14:19:41.761Z Scientists Built a Cell From Scratch. It Eats, Grows, and Divides. But Is It Alive? https://biotechmorning.com/news/rfk-jr-covid-vaccine-injury-table Biotech Morning en 2026-07-30T14:21:27.473Z The Federal Government Wants to Make a List of Covid Vaccine Injuries https://biotechmorning.com/news/fate-therapeutics-car-t-systemic-sclerosis Biotech Morning en 2026-07-30T14:20:38.416Z The Cancer Drug That's Learning New Tricks in Autoimmune Disease https://biotechmorning.com/news/deramiocel-adcom-vote-duchenne-cardiomyopathy Biotech Morning en 2026-07-30T14:19:44.809Z The Cell Therapy That Couldn't Convince 9 Out of 12 Experts https://biotechmorning.com/news/lytenava-fda-approval-three-rejections Biotech Morning en 2026-07-30T14:18:57.056Z The Eye Drug That Took Three Rejections to Finally Win Over the FDA https://biotechmorning.com/news/setanaxib-nox-inhibitor-pbc-liver-disease-transform-trial Biotech Morning en 2026-07-30T14:18:04.084Z The First-in-Class Drug Attacking Liver Disease at Its Rusty Roots